Melanoma (Skin) Clinical Trial
Official title:
MoleGazer: A Feasibility Study for Early Detection of Melanoma
Melanoma (skin cancer) frequently develops from existing moles on the skin. Current practice relies on expert dermatologists being able to successfully identify new/changing moles in individuals with multiple moles. Total body photography (TBP-high-quality images of the entire skin) can track and monitor moles over time to detect melanoma. However, TBP is currently used as a visual guide when diagnosing melanoma, requiring visual inspection of each mole sequentially. This process is challenging, time-consuming and inefficient. Artificial intelligence (AI) is ideally suited to automate this process. Comparing baseline TBP images to newly acquired photographs, AI techniques can be used to accurately identify and highlight changing moles, and potentially distinguish harmless moles from cancerous changes. Astrophysicists face a similar problem when they map the night sky to detect new events, such as exploding stars. Using AI, based on two or more images, astrophysicists detect new events and accurately predict how they will appear subsequently. This project, called MoleGazer, is a collaboration with astrophysicists aiming to apply AI methods that are currently used for astronomical sky surveys, to TBP images. The MoleGazer algorithm, developed at Oxford University Hospitals NHS Foundation Trust, will automatically identify the appearance of new moles and characterise changes in existing ones, when new TBP images are taken. To optimise this MoleGazer algorithm TBP images will be taken at multiple time-points, as there are no existing datasets of TBP images that are publicly available. The investigators invite a) high-risk patients attending skin cancer screening clinics to attend sequential three-monthly TBP imaging and clinical assessment and b) any patient who undergoes TBP as standard care to share images so that the investigators can develop the MoleGazer algorithm. The ultimate goal is for the MoleGazer algorithm to 'map moles' over a patient's lifetime to detect changes, with the eventual aim to detect melanoma as early as possible.
Status | Recruiting |
Enrollment | 550 |
Est. completion date | February 12, 2026 |
Est. primary completion date | February 28, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Participant is willing and able to give informed consent for participation in the study - Male or Female, aged 18-80 years old In addition for Group A: 1. Willing to attend for additional study visits and total body photography imaging 2. High-risk melanoma patients including: - Dysplastic / atypical naevus syndrome (> 60 moles +/- personal history of melanoma) - Family history of melanoma - Past history of at least two primary melanoma or melanoma-in situ - At least 3 first-degree or second-degree relatives with prior melanoma - CDKN2A or CDK4 germline mutation - Individuals with multiple naevi (>25) who are immunosuppressed from any cause (e.g. organ transplant recipients, chronic lymphocytic leukaemia, etc.) In addition for Group B: ? Has previously had total body photography imaging OR will have total body photography as part of standard care Exclusion Criteria: The participant may not enter the study if ANY of the following apply: - Patient unable to consent - Patient with active malignancy affecting any organ and receiving any cancer-specific treatment - Poor mobility / unable to hold recommended positions for standard TBP imaging - Individuals who do not understand English In addition for Group A: ? Unable to attend for three-monthly study visits |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Churchill Hospital | Headington | Oxford |
Lead Sponsor | Collaborator |
---|---|
Oxford University Hospitals NHS Trust | University of Southampton |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional algorithm to map naevi sequentially | The primary objective of this study is to develop the MoleGazer algorithm | 3 years | |
Primary | Number of TBP images in database | To develop an anonymised database of digital total body photography images | 3 years | |
Secondary | Proportion of high quality images amenable to evaluation | Assess the quality of TBP images | 3 years | |
Secondary | The proportion of participants who complete a dataset of three-monthly imaging (Group A) | Determine feasibility of patients obtaining regular TBP imaging | 2 years | |
Secondary | The proportion of TBP images that can be registered and consistently deformed using existing astronomical software adapted for this purpose | To demonstrate consistently registering all images for use in sequential imaging | 1 year | |
Secondary | The number of naevi detected by our algorithm from TBP images compared to those determined by an experienced dermatologist | To detect all naevi in each TBP image | 1 year | |
Secondary | The distribution of naevi detected by our algorithm from TBP images compared to those determined by an experienced dermatologist | To detect distribution of all naevi in each TBP image | 1 year | |
Secondary | The proportion of naevi (as determined by a trained dermatologist) in TBP images discarded when considering an optimal feature set | To determine a feature set that distinguished between naevi and other skin lesions | 3 years | |
Secondary | The proportion of sequential TBP images that can be used for naevi detection. | To develop a database structure to track the evolution of each detected naevus | 3 years | |
Secondary | The proportion of naevi that are detected and measured in all sequential TBP images | To study the evolutionary path of naevi in sequential TBP images | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04062032 -
Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma
|
Phase 2 | |
Completed |
NCT03620019 -
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Completed |
NCT00962845 -
Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT00324623 -
Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma
|
Phase 1 | |
Completed |
NCT00096382 -
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00104845 -
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 1 | |
Completed |
NCT00089193 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00072124 -
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
|
Phase 3 | |
Completed |
NCT00072085 -
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT00039234 -
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
|
Phase 3 | |
Completed |
NCT00042783 -
Vaccine Therapy in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Completed |
NCT00049010 -
Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
|
N/A | |
Completed |
NCT00006385 -
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00006022 -
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
|
Phase 1 | |
Completed |
NCT00005610 -
Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung
|
Phase 2 | |
Completed |
NCT00020358 -
Vaccine Therapy in Treating Patients With Melanoma
|
Phase 2 | |
Recruiting |
NCT03767348 -
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
|
Phase 2 | |
Withdrawn |
NCT00006126 -
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
|
Phase 1 |